JosephRonaldMaceMD

PubMed

• 100 citations
  Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a ra...
  Thierry Facon, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldsc...> ;The Lancet. Oncology. 2021 Oct 13
• 5 citations
  A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-...
  Jesus G. Berdeja, Tara K. Gregory, Edward A. Faber, Lowell L. Hart, Joseph R. Mace, Edward Arrowsmith, Ian W. Flinn, Jeffrey V. Matous> ;American Journal of Hematology. 2021 Jan 9
• 11 citations
  Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy
  Ian W. Flinn, Jack Erter, Davey B. Daniel, Joseph R. Mace, Jesus G. Berdeja> ;The Oncologist. 2019 Aug 1
• 59 citations
  Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
  Guillermo Garcia-Manero, Gail J. Roboz, Katherine Walsh, Hagop M. Kantarjian, Ellen K. Ritchie, Patricia Kropf, Casey O'Connell, Raoul Tibes, Scott D. Lunin, Todd L. R...> ;The Lancet. Haematology. 2019 Jun 1
• 585 citations
  Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
  Thierry Facon, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldsc...> ;The New England Journal of Medicine. 2019 May 29
• 38 citations
  A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer
  Johanna C. Bendell, Howard S. Hochster, Lowell L. Hart, Irfan Firdaus, Joseph R. Mace, Joshua J. McFarlane, Mark Kozloff, Daniel V.T. Catenacci, Jessie J. Hsu, Stephen...> ;The Oncologist. 2017 Mar 1
• 38 citations
  A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Car...
  John D. Hainsworth, James A. Reeves, Joseph R. Mace, Edward J. Crane, Oday Hamid, John R. Stille, Amy Flynt, Stephanie Roberson, John Polzer, Edward Arrowsmith> ;Targeted Oncology. 2016 May 7
• 76 citations
  Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
  Jesus G. Berdeja, Lowell L. Hart, Joseph R. Mace, Edward Arrowsmith, James Essell, Rami Owera, John D. Hainsworth, Ian W. Flinn> ;Haematologica. 2015 May 1
• 13 citations
  Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage IIIB/IV Non–Sma...
  Philip Bonomi, Joseph Mace, Romeo A. Mandanas, Myo Min, Mark R. Olsen, Hagop Youssoufian, Terry L. Katz, Grishma Sheth, Hyun Jung Lee> ;Journal of Thoracic Oncology. 2013 Mar 1
• 1 citations
  Radioimmunotherapy in follicular lymphoma: an update.
  Joseph R Mace> ;Clinical Advances in Hematology & Oncology. 2012 Jun 1
• Phase II randomized, open-label study of cetuximab (Cet) and bevacizumab (Bev) in combination with paclitaxel (P) and carboplatin (C) in patients with stageIII/IV non-...
  Bonomi PD, Mace J, Mandanas RD, Min M, Zhang Y, Rowinsky E, Youssoufian H> ;J. Clin. Oncol.. 2009-05-20
• 60 citations
  Phase II Study of 9-Nitro-Camptothecin in Patients With Advanced Chordoma or Soft Tissue Sarcoma
  Rashmi Chugh, Rodney L. Dunn, Mark M. Zalupski, J. Sybil Biermann, Vernon K. Sondak, Joseph R. Mace, Kirsten M. Leu, William F. Chandler, Laurence H. Baker> ;Journal of Clinical Oncology. 2005 May 20
• 15 citations
  Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
  Joseph R. Mace, Mary L. Keohan, Heinz Bernardy, Klaus Junge, Georg Niebch, Peter Romeis, Aangelika Thoma, T. Wagner, Udo Mueller, George D. Demetri, Laurence H. Baker> ;Clinical Cancer Research. 2003 Dec 1
• 144 citations
  Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
  Joseph Mace, J. Sybil Biermann, Vernon Sondak, Cornelius McGinn, Curtis Hayes, Dafydd G. Thomas, D O Laurence Baker> ;Cancer. 2002 Dec 1
• Join now to see all

Lectures

• Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018